Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Inactivated H7N9 Influenza Vaccine
NCT03369808Phase 2Completed
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Dec 2017
- Primary completion
- Aug 2018
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in avian influenza A H7N9 virus infection (H7N9) (5 arms), sponsored by Shanghai Institute of Biological Products. Primary endpoint: Reactogenicity Events at 30 days. Started Dec 2017; status: completed.
02
Conditions
avian influenza A H7N9 virus infection (H7N9)
Beyond the preview
Go deeper on NCT03369808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03369808.